Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Device Tax Delay? 18 Senate Dems Say ‘Yes’; Obama Says ‘No’

This article was originally published in The Gray Sheet

Executive Summary

Potential delay of the device tax seemed to gain momentum with a recent letter from 18 Senate Democrats to Senate Majority Leader Reid, but the president and Senate Finance Committee leadership are not on board.

You may also be interested in...



Ultimate Burden Of Device Tax – After Deductions – Debated At Senate Hearing

Sen. Debbie Stabenow, D-Mich., said the harsh impact of the device tax on industry after deductions are accounted for is less than a B. Braun official at an April 23 Senate Finance Health Care Subcommittee claims.

Long-Time HELP Democrat Sen. Barbara Mikulski Plans To Retire By 2017

Maryland Sen. Barbara Mikulski (D), the body’s longest-serving female Senator, former Appropriations Committee Chair and advocate of quality and comparative effectiveness provisions in the Affordable Care Act, recently announced her plans not to seek re-election in 2016 and retire.

Device Tax Delay Doesn’t Make The Cut, But Issue Could Be Exhumed In Budget Conference

Despite being a factor in lawmaker discussions throughout the shutdown, provisions to delay or repeal the device tax did not survive in the final agreement to reopen the federal government and raise the debt ceiling. But the issue appeared to gain more momentum than ever that companies hope can be maintained into upcoming budget conference talks.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT031813

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel